Encompass Health Co. (NYSE:EHC) Position Increased by Axa S.A.

Axa S.A. raised its stake in Encompass Health Co. (NYSE:EHC) by 132.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 66,866 shares of the company’s stock after buying an additional 38,117 shares during the period. Axa S.A. owned approximately 0.07% of Encompass Health worth $6,175,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of EHC. MassMutual Private Wealth & Trust FSB boosted its position in shares of Encompass Health by 87.8% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock valued at $27,000 after purchasing an additional 137 shares during the period. Transce3nd LLC acquired a new position in shares of Encompass Health in the fourth quarter worth about $40,000. CBIZ Investment Advisory Services LLC increased its position in shares of Encompass Health by 38.7% in the fourth quarter. CBIZ Investment Advisory Services LLC now owns 455 shares of the company’s stock worth $42,000 after acquiring an additional 127 shares in the last quarter. Tompkins Financial Corp purchased a new stake in shares of Encompass Health in the 4th quarter valued at approximately $46,000. Finally, V Square Quantitative Management LLC boosted its stake in Encompass Health by 43.8% in the 4th quarter. V Square Quantitative Management LLC now owns 581 shares of the company’s stock worth $54,000 after purchasing an additional 177 shares during the period. 97.25% of the stock is owned by institutional investors.

Encompass Health Stock Performance

Shares of EHC opened at $117.02 on Wednesday. The company has a quick ratio of 1.04, a current ratio of 1.05 and a debt-to-equity ratio of 0.84. Encompass Health Co. has a 12 month low of $82.74 and a 12 month high of $117.98. The company’s fifty day moving average is $102.40 and its 200-day moving average is $99.52. The firm has a market cap of $11.78 billion, a price-to-earnings ratio of 26.24, a price-to-earnings-growth ratio of 2.31 and a beta of 0.91.

Encompass Health (NYSE:EHC) last posted its earnings results on Thursday, April 24th. The company reported $1.37 earnings per share for the quarter, beating the consensus estimate of $1.19 by $0.18. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Encompass Health had a return on equity of 17.56% and a net margin of 8.48%. The business’s revenue was up 10.6% compared to the same quarter last year. During the same period last year, the company earned $1.12 earnings per share. Equities analysts expect that Encompass Health Co. will post 4.8 EPS for the current fiscal year.

Encompass Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Tuesday, July 1st will be issued a dividend of $0.17 per share. The ex-dividend date of this dividend is Tuesday, July 1st. This represents a $0.68 annualized dividend and a yield of 0.58%. Encompass Health’s dividend payout ratio (DPR) is presently 14.05%.

Insider Activity

In other news, CAO Andrew L. Price sold 5,042 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $98.29, for a total transaction of $495,578.18. Following the completion of the transaction, the chief accounting officer now directly owns 69,164 shares in the company, valued at $6,798,129.56. The trade was a 6.79 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John Patrick Darby sold 10,000 shares of the firm’s stock in a transaction on Tuesday, April 29th. The stock was sold at an average price of $114.79, for a total transaction of $1,147,900.00. Following the completion of the sale, the executive vice president now owns 79,710 shares in the company, valued at approximately $9,149,910.90. The trade was a 11.15 % decrease in their position. The disclosure for this sale can be found here. Insiders own 2.00% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on EHC shares. Truist Financial restated a “buy” rating and issued a $135.00 target price (up previously from $116.00) on shares of Encompass Health in a report on Monday, April 28th. StockNews.com cut Encompass Health from a “buy” rating to a “hold” rating in a research note on Saturday. UBS Group increased their price target on shares of Encompass Health from $117.00 to $130.00 and gave the stock a “buy” rating in a research report on Monday, April 28th. Barclays boosted their price objective on shares of Encompass Health from $118.00 to $129.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Finally, William Blair reiterated an “outperform” rating on shares of Encompass Health in a research report on Friday, February 7th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $120.86.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.